Torray LLC lifted its stake in Amgen, Inc. (NASDAQ:AMGN) by 8.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 11,641 shares of the medical research company’s stock after purchasing an additional 892 shares during the period. Torray LLC’s holdings in Amgen were worth $2,413,000 as of its most recent SEC filing.
Other large investors also recently bought and sold shares of the company. Kwmg LLC purchased a new position in Amgen during the 2nd quarter valued at about $108,000. Mainstay Capital Management LLC ADV purchased a new position in Amgen during the 2nd quarter valued at about $111,000. Polaris Greystone Financial Group LLC purchased a new position in Amgen during the 3rd quarter valued at about $166,000. Dixon Hubard Feinour & Brown Inc. VA purchased a new position in Amgen during the 2nd quarter valued at about $200,000. Finally, Family Firm Inc. purchased a new position in Amgen during the 2nd quarter valued at about $202,000. 82.37% of the stock is owned by hedge funds and other institutional investors.
A number of research analysts recently issued reports on AMGN shares. Zacks Investment Research raised shares of Amgen from a “hold” rating to a “buy” rating and set a $234.00 price target for the company in a research report on Monday, October 1st. Citigroup lifted their target price on shares of Amgen from $188.00 to $200.00 and gave the stock a “neutral” rating in a report on Monday, July 30th. Mizuho reaffirmed a “buy” rating and issued a $206.00 target price on shares of Amgen in a report on Friday, October 26th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Amgen in a report on Thursday, October 25th. Finally, Robert W. Baird lifted their target price on shares of Amgen from $165.00 to $179.00 and gave the stock a “neutral” rating in a report on Monday, July 30th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $204.55.
Shares of AMGN stock opened at $193.16 on Friday. Amgen, Inc. has a 52 week low of $163.31 and a 52 week high of $210.19. The company has a market capitalization of $125.93 billion, a PE ratio of 15.35, a P/E/G ratio of 2.05 and a beta of 1.37. The company has a debt-to-equity ratio of 2.05, a current ratio of 3.08 and a quick ratio of 2.84.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, October 30th. The medical research company reported $3.69 EPS for the quarter, topping analysts’ consensus estimates of $3.45 by $0.24. Amgen had a net margin of 9.44% and a return on equity of 54.14%. The firm had revenue of $5.90 billion during the quarter, compared to analyst estimates of $5.78 billion. During the same period in the previous year, the business posted $3.27 earnings per share. The business’s revenue for the quarter was up 2.3% on a year-over-year basis. Equities research analysts anticipate that Amgen, Inc. will post 14.24 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 7th. Stockholders of record on Friday, November 16th will be paid a $1.32 dividend. The ex-dividend date of this dividend is Thursday, November 15th. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.73%. Amgen’s dividend payout ratio is presently 41.97%.
TRADEMARK VIOLATION NOTICE: This piece of content was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/11/10/amgen-inc-amgn-shares-bought-by-torray-llc.html.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Featured Article: Should You Consider an Index Fund?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.